MCK Stock Overview
Provides healthcare services in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Leveraging AI And Decisive Partnerships Boosts Growth In Oncology And Biopharma, Outpacing Market Challenges
US$611.7
FV
10.72%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative
McKesson Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$629.09 |
52 Week High | US$631.37 |
52 Week Low | US$404.72 |
Beta | 0.45 |
11 Month Change | 7.57% |
3 Month Change | 18.95% |
1 Year Change | 44.58% |
33 Year Change | 215.06% |
5 Year Change | 347.75% |
Change since IPO | 3,712.67% |
Recent News & Updates
Recent updates
McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus
Oct 08McKesson extends distribution partnership with CVS Health
Sep 29An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued
Sep 19McKesson to acquire Rx Savings Solutions in $875M deal
Sep 19Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD
Aug 15McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results
Aug 03McKesson raises dividend by 15% to $0.54/share
Jul 25McKesson Is Still An Attractive Dividend Growth Stock
Jul 10Shareholder Returns
MCK | US Healthcare | US Market | |
---|---|---|---|
7D | 5.6% | 2.2% | 0.3% |
1Y | 44.6% | 8.0% | 18.6% |
Return vs Industry: MCK exceeded the US Healthcare industry which returned 8% over the past year.
Return vs Market: MCK exceeded the US Market which returned 18.6% over the past year.
Price Volatility
MCK volatility | |
---|---|
MCK Average Weekly Movement | 2.1% |
Healthcare Industry Average Movement | 7.2% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 14.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MCK has not had significant price volatility in the past 3 months.
Volatility Over Time: MCK's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
MCK fundamental statistics | |
---|---|
Market cap | US$80.03b |
Earnings (TTM) | US$3.00b |
Revenue (TTM) | US$308.95b |
27.2x
P/E Ratio0.3x
P/S RatioIs MCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MCK income statement (TTM) | |
---|---|
Revenue | US$308.95b |
Cost of Revenue | US$296.37b |
Gross Profit | US$12.58b |
Other Expenses | US$9.58b |
Earnings | US$3.00b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
Earnings per share (EPS) | 23.14 |
Gross Margin | 4.07% |
Net Profit Margin | 0.97% |
Debt/Equity Ratio | -342.2% |
How did MCK perform over the long term?
See historical performance and comparison